IQVIA is updating its analysis of the 340B program’s financial impact on state healthcare purchasers, including employers, workers, and managed Medicaid plans. This refreshed study builds on prior research and reflects more than 93 percent growth in the cost to employers nationally since the original assessment. Additionally, 340B costs state managed Medicaid programs $4.2 billions in terms of displaced rebates in 2025.

Using drug claims and health plan premium data, our new research is summarized with methods, findings, and key insights. This details analysis is summarized in the Cost of the 340B Program to States, along with 50 state (and D.C.) summaries to support policy makers and stakeholders evaluating 304B’s impact